RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCIE SCOPUS

      High Expression of Urokinase-Type Plasminogen Activator Is Associated with Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast

      한글로보기

      https://www.riss.kr/link?id=A104426056

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Purpose: In the present study, we evaluated the levels of urokinase- type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1) by performing immunohistochemical staining to determine whether they were reliable prognostic markers in patients with breast cancer. Methods: Demographic and clinicopathological parameters of 214 patients with invasive ductal carcinoma (IDC) and 80 patients with ductal carcinoma in situ (DCIS) who were diagnosed and treated from 2006 to 2010 were analyzed. Tissue microarray was constructed and immunohistochemical staining was performed for each specimen. Results: Univariate analyses showed that age at diagnosis, history of hormone replacement therapy, radiation therapy, skin and chest wall invasion, Paget disease, lymphovascular invasion, estrogen receptor positivity, and triple-negative subtype were significantly associated with patient prognosis (p<0.005). Patients with DCIS showed higher PAI-1 expression than patients with IDC (82.5% and 36.2%, respectively; p=0.012). Lymph node metastasis was more frequent in patients with high uPA levels than in patients with low uPA levels (p=0.001). Conclusion: Our results suggested that PAI-1 was involved in tumor progression in the early stages of breast cancer, such as DCIS. In addition, our results suggested that high uPA levels were associated with the lymph node metastasis of IDC.
      번역하기

      Purpose: In the present study, we evaluated the levels of urokinase- type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1) by performing immunohistochemical staining to determine whether they were reliable prognostic markers i...

      Purpose: In the present study, we evaluated the levels of urokinase- type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1) by performing immunohistochemical staining to determine whether they were reliable prognostic markers in patients with breast cancer. Methods: Demographic and clinicopathological parameters of 214 patients with invasive ductal carcinoma (IDC) and 80 patients with ductal carcinoma in situ (DCIS) who were diagnosed and treated from 2006 to 2010 were analyzed. Tissue microarray was constructed and immunohistochemical staining was performed for each specimen. Results: Univariate analyses showed that age at diagnosis, history of hormone replacement therapy, radiation therapy, skin and chest wall invasion, Paget disease, lymphovascular invasion, estrogen receptor positivity, and triple-negative subtype were significantly associated with patient prognosis (p<0.005). Patients with DCIS showed higher PAI-1 expression than patients with IDC (82.5% and 36.2%, respectively; p=0.012). Lymph node metastasis was more frequent in patients with high uPA levels than in patients with low uPA levels (p=0.001). Conclusion: Our results suggested that PAI-1 was involved in tumor progression in the early stages of breast cancer, such as DCIS. In addition, our results suggested that high uPA levels were associated with the lymph node metastasis of IDC.

      더보기

      참고문헌 (Reference)

      1 Malinowsky K, "uPA and PAI-1-related signaling pathways differ between primary breast cancers and lymph node metastases" 5 : 98-104, 2012

      2 Duffy MJ, "uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies" 16 : 428-, 2014

      3 Lamy PJ, "Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression" 128 : 404-413, 2007

      4 Duffy MJ, "Urokinase-plasminogen activator, a marker for aggressive breast carcinomas:preliminary report" 62 : 531-533, 1988

      5 Duffy MJ, "The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer" 37 : 541-548, 2004

      6 Tang L, "The urokinase plasminogen activator system in breast cancer invasion and metastasis" 67 : 179-182, 2013

      7 Harbeck N, "Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients" 49 : 1825-1835, 2013

      8 Remmele W, "Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue" 8 : 138-140, 1987

      9 Jänicke F, "Randomized adjuvant chemotherapy trial in high-risk, lymph nodenegative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1" 93 : 913-920, 2001

      10 Duffy MJ, "Proteases as prognostic markers in cancer" 2 : 613-618, 1996

      1 Malinowsky K, "uPA and PAI-1-related signaling pathways differ between primary breast cancers and lymph node metastases" 5 : 98-104, 2012

      2 Duffy MJ, "uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies" 16 : 428-, 2014

      3 Lamy PJ, "Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression" 128 : 404-413, 2007

      4 Duffy MJ, "Urokinase-plasminogen activator, a marker for aggressive breast carcinomas:preliminary report" 62 : 531-533, 1988

      5 Duffy MJ, "The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer" 37 : 541-548, 2004

      6 Tang L, "The urokinase plasminogen activator system in breast cancer invasion and metastasis" 67 : 179-182, 2013

      7 Harbeck N, "Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients" 49 : 1825-1835, 2013

      8 Remmele W, "Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue" 8 : 138-140, 1987

      9 Jänicke F, "Randomized adjuvant chemotherapy trial in high-risk, lymph nodenegative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1" 93 : 913-920, 2001

      10 Duffy MJ, "Proteases as prognostic markers in cancer" 2 : 613-618, 1996

      11 Kantelhardt EJ, "Prospective evaluation of prognostic factors uPA/PAI-1 in nodenegative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel" 11 : 140-, 2011

      12 Saadoun H, "Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer" 10 : 195-209, 2014

      13 Look MP, "Pooled analysis of prognostic impact of urokinasetype plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients" 94 : 116-128, 2002

      14 Castelló R, "Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity" 117 : 487-492, 2006

      15 Lei H, "PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer" 109 : 165-175, 2008

      16 Lang DS, "Optimized immunohistochemistry in combination with image analysis: a reliable alternative to quantitative ELISA determination of uPA and PAI-1 for routine risk group discrimination in breast cancer" 22 : 736-743, 2013

      17 Isaacs C, "New prognostic factors for breast cancer recurrence" 28 : 53-67, 2001

      18 Haas S, "Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue" 452 : 277-283, 2008

      19 Hansen S, "Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients" 88 : 102-108, 2003

      20 Christensen L, "Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas" 66 : 441-452, 1996

      21 Roca C, "Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism" 63 : 1500-1507, 2003

      22 Bajou K, "Hostderived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth" 23 : 6986-6990, 2004

      23 Andres SA, "Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance" 26 : 93-103, 2012

      24 Soff GA, "Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model" 96 : 2593-2600, 1995

      25 Dass K, "Evolving role of uPA/uPAR system in human cancers" 34 : 122-136, 2008

      26 Leik CE, "Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis" 4 : 2710-2715, 2006

      27 Ferrier CM, "Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue" 79 : 1534-1541, 1999

      28 Jänicke F, "Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer" 17 : 303-312, 1991

      29 Schmitt M, "Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1" 11 : 617-634, 2011

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2020-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2011-04-06 학술지명변경 외국어명 : Journal of Korean Breast Cancer -> Journal of Breast Cancer KCI등재
      2011-03-23 학술지명변경 외국어명 : Journal of Korean Breast Cancer -> 미등록 KCI등재
      2011-03-04 학술지명변경 한글명 : 한국유방암학회지 -> Journal of Breast Cancer KCI등재
      2011-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2010-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2008-01-01 평가 SCIE 등재 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 1.99 0.19 1.31
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.96 0.77 0.448 0.06
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼